Status:
COMPLETED
Continuation of Follow-up of DES-Exposed Cohorts
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Autoimmune Disease
Eligibility:
All Genders
18-100 years
Brief Summary
Diethylstilbestrol (DES), a drug first synthesized in 1938, was administered to several million pregnant women in the U.S. and Europe for the prevention of spontaneous abortion and premature delivery....
Detailed Description
Diethylstilbestrol (DES), a drug first synthesized in 1938, was administered to several million pregnant women in the U.S. and Europe for the prevention of spontaneous abortion and premature delivery....
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Exposed daughters and unexposed daughters originally identified at: Baylor College of Medicine, University of Southern California (USC), Gunderson Clinic, Mayo Clinic, and Massachusetts General Hospital (MGH).
- Male and female offspring of mothers who were enrolled in a clinical trial to assess the effectiveness of DES at the University of Chicago.
- Offspring of mothers who were treated with DES by an infertility specialist, Dr. Herbert Horne, in the Boston area.
- Offspring of DES-exposed mothers and unexposed mothers who were followed for breast cancer risk during the 1980s.
- Exposed sons and unexposed sons who were originally identified and followed at the Mayo Clinic during the late1970's for the occurrence of cancer, genital abnormalities and infertility.
- Subjects from the Registry for Research on Hormonal Transplacental Carcinogenesis.
Exclusion
Key Trial Info
Start Date :
March 18 1998
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 13 2020
Estimated Enrollment :
10805 Patients enrolled
Trial Details
Trial ID
NCT00340600
Start Date
March 18 1998
End Date
November 13 2020
Last Update
November 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston University School of Public Health
Boston, Massachusetts, United States, 02118-2354